Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.
Okhuijsen-Pfeifer C, van der Horst MZ, Bousman CA, Lin B, van Eijk KR, Ripke S, Ayhan Y, Babaoglu MO, Bak M, Alink W, van Beek H, Beld E, Bouhuis A, Edlinger M, Erdogan IM, Ertuğrul A, Yoca G, Everall IP, Görlitz T; GROUP (Genetic Risk and Outcome of Psychosis) investigators; Grootens KP, Gutwinski S, Hallikainen T, Jeger-Land E, de Koning M, Lähteenvuo M, Legge SE, Leucht S, Morgenroth C, Müderrisoğlu A, Narang A, Pantelis C, Pardiñas AF, Oviedo-Salcedo T, Schneider-Thoma J, Schreiter S, Repo-Tiihonen E, Tuppurainen H, Veereschild M, Veerman S, de Vos M, Wagner E, Cohen D, Bogers JPAM, Walters JTR, Yağcıoğlu AEA, Tiihonen J, Hasan A, Luykx JJ.
Okhuijsen-Pfeifer C, et al. Among authors: muderrisoglu a.
Transl Psychiatry. 2022 Apr 7;12(1):145. doi: 10.1038/s41398-022-01884-3.
Transl Psychiatry. 2022.
PMID: 35393395
Free PMC article.